Tucatinib Gives PFS Boost for Metastatic Breast Cancer.
1/5 보강
The addition of the HER2 tyrosine kinase inhibitor tucatinib to trastuzumab and pertuzumab as first-line maintenance therapy significantly increased progression-free survival (PFS) compared to a place
APA
(2026). Tucatinib Gives PFS Boost for Metastatic Breast Cancer.. Cancer discovery, 16(3), OF1. https://doi.org/10.1158/2159-8290.CD-NW2025-0111
MLA
. "Tucatinib Gives PFS Boost for Metastatic Breast Cancer.." Cancer discovery, vol. 16, no. 3, 2026, pp. OF1.
PMID
41405216 ↗
Abstract 한글 요약
The addition of the HER2 tyrosine kinase inhibitor tucatinib to trastuzumab and pertuzumab as first-line maintenance therapy significantly increased progression-free survival (PFS) compared to a placebo plus mAb treatment for patients with HER2-positive metastatic breast cancer. The findings position it alongside trastuzumab deruxtecan and palbociclib as agents that have demonstrated impressive PFS improvements in phase III studies.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.